Targeting HMGB1 in endothelial cells reverses heme-induced SIRS after radiofrequency ablation of hepatic hemangioma
Frontiers in Immunology · 2025
DOI: 10.3389/fimmu.2025.1680433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Changyu Yao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: HMGB1 Protein, Hemangioma, Heme, Systemic Inflammatory Response Syndrome. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Background
Although radiofrequency ablation (RFA) is a safe and effective treatment for hepatic hemangiomas, post-RFA systemic inflammatory response syndrome (SIRS) frequently occurs. The role of high-mobility group box 1 (HMGB1) in endothelial cell pyroptosis and SIRS induction following RFA in hepatic hemangiomas remains unexplored.
Methods
In vitro , the levels of interleukin (IL)-1β, IL-18, and pyroptosis markers, such as GSDMD-N and Casp1 p20, were measured in human umbilical vein endothelial cells (HUVECs) after heme administration. In vivo , an orthotopic liver hemangioma mouse model was established, and RFA was performed to evaluate the levels of IL-1β and IL-18, wet-to-dry lung ratio, and inflammation score. In addition, hemopexin and glycyrrhizin were used to investigate the impact of HMGB1 on heme-induced SIRS post-RFA in hepatic hemangioma mice.
Results
Heme induced elevated levels of IL-1β and IL-18, endothelial cell death in vitro , and increased wet-to-dry lung ratio and inflammation score in vivo . These effects were rescued with the administration of heme-binding protein hemopexin, indicating the role of heme in inducing SIRS and pyroptosis post-RFA of hepatic hemangioma. HMGB1 participates in heme-induced SIRS in mice by regulating HMGB1/nod-like receptor family pyrin domain-containing 3 (NLRP3) pathway through reactive oxygen species (ROS). Treatment with hemopexin or the HMGB1 inhibitor glycyrrhizin reversed heme-induced SIRS after RFA of hepatic hemangioma in mice.
Conclusions
Collectively, we demonstrated that heme induces SIRS through the ROS/HMGB1/NLRP3 pathway-regulated endothelial cell pyroptosis in mice, and hemopexin, a heme scavenger, and glycyrrhizin, a HMGB1 inhibitor, may be the potential strategies for further study for SIRS following the RFA of hepatic hemangioma for the first time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
- Department of Pathology, Peking University People's Hospital, Peking University, Beijing, China.
- Department of Anesthesiology, Peking University People's Hospital, Peking University, Beijing, China.
Förderung
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Yao, C., Zhou, Y., Yu, L., Xu, L., Wu, S., Gao, R., Hou, Y., Sun, W., Gao, J., & Wang, S. (2025). Targeting HMGB1 in endothelial cells reverses heme-induced SIRS after radiofrequency ablation of hepatic hemangioma. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1680433
Vancouver
Yao C, Zhou Y, Yu L, Xu L, Wu S, Gao R, et al. Targeting HMGB1 in endothelial cells reverses heme-induced SIRS after radiofrequency ablation of hepatic hemangioma. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1680433
BibTeX
@article{Yao2025,
author = {Yao, Changyu and Zhou, Ying and Yu, Liuyang and Xu, Li and Wu, Shilun and Gao, Ruize and Hou, Yirui and Sun, Wenbing and Gao, Jun and Wang, Shaohong},
title = {Targeting HMGB1 in endothelial cells reverses heme-induced SIRS after radiofrequency ablation of hepatic hemangioma},
journal = {Frontiers in Immunology},
year = {2025},
doi = {10.3389/fimmu.2025.1680433}
}
EUVIMED